Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
SUPN Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call highlights a 12% YoY revenue growth and a 25% increase in net income, driven by strong product sales and effective cost management. EPS growth aligns with net income, and positive cash flow indicates strong financial health. Despite no updates on strategic initiatives or shareholder returns, the raised revenue guidance and decreased operating loss forecast are positive indicators. The market cap suggests moderate volatility, supporting a positive sentiment prediction.
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Neutral12-8
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several negative indicators: increased operating loss guidance due to Sage acquisition costs, cash reserves depletion, and unresolved supply constraints for Onapgo. Although revenue guidance was raised, the uncertainty surrounding Q4 sales and evasive management responses in the Q&A suggest potential risks. The stock is likely to react negatively, especially given the small-cap market cap, which typically shows higher volatility.
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reflects strong financial performance with increased net earnings and a healthy cash position. Product launches, particularly ONAPGO and Qelbree, show promising growth and market acceptance. The company’s optimistic guidance, strategic focus on CNS and women's health, and successful reimbursement processes are positive indicators. Despite some concerns about operating earnings and management's lack of specific details on ZURZUVAE, the overall sentiment is positive, especially with new product momentum and strategic partnerships. Given the market cap, a positive stock price movement between 2% to 8% is expected.
SUPN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
